Cresset Asset Management LLC Sells 33,523 Shares of Genmab A/S (NASDAQ:GMAB)

Cresset Asset Management LLC reduced its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 56.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,752 shares of the company's stock after selling 33,523 shares during the quarter. Cresset Asset Management LLC's holdings in Genmab A/S were worth $537,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Brandywine Global Investment Management LLC purchased a new position in shares of Genmab A/S in the 4th quarter worth about $33,804,000. Marshall Wace LLP grew its holdings in Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock valued at $23,422,000 after purchasing an additional 694,243 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Genmab A/S during the 4th quarter valued at $12,360,000. Russell Investments Group Ltd. grew its stake in shares of Genmab A/S by 18,959.1% during the 4th quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock worth $10,660,000 after acquiring an additional 508,104 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Genmab A/S by 3,049.3% in the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock worth $8,507,000 after acquiring an additional 394,670 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Trading Up 0.4%

Shares of NASDAQ GMAB traded up $0.08 during midday trading on Tuesday, hitting $20.26. 219,673 shares of the company's stock were exchanged, compared to its average volume of 1,108,462. The business's fifty day moving average price is $19.74 and its two-hundred day moving average price is $20.73. The company has a market cap of $12.99 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 2.65 and a beta of 1.04. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $30.06.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The firm had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Equities analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

GMAB has been the topic of several recent research reports. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. HC Wainwright restated a "buy" rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Truist Financial lowered their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Finally, BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.